Timothy Lu 4

4 · DICE Therapeutics, Inc. · Filed Sep 16, 2021

Form 4

Period: 2021-09-14

CMO

Transactions

Award
Stock Option (right to buy)
2021-09-14+25,593→ 25,593 total
Exercise: $17.00Exp: 2031-09-14→ Common Stock (25,593 underlying)
Award
Stock Option (right to buy)
2021-09-14+25,817→ 25,817 total
Exercise: $17.00Exp: 2031-09-14→ Common Stock (25,817 underlying)
Award
Stock Option (right to buy)
2021-09-14+17,350→ 17,350 total
Exercise: $17.00Exp: 2031-09-14→ Common Stock (17,350 underlying)
Award
Stock Option (right to buy)
2021-09-14+31,304→ 31,304 total
Exercise: $17.00Exp: 2031-09-14→ Common Stock (31,304 underlying)

Holdings

Footnotes (5)

[F1]The number of shares of Common Stock reported in the Reporting Holder's Form 3 reflected the conversion of derivative securities based on the midpoint of the Issuer's initial public offering range of $16.00 per share. The number of shares of Common Stock reflected in this Form 4 reflects the adjusted number of shares issued based on the higher initial public offering price of $17.00 per share, and does not reflect a disposition of shares.
[F2]Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met.
[F3]The option vests as to 1/4 of the total shares on August 24, 2020, and then 1/48th of the total shares vest monthly, subject to the Reporting Holder's continuing employment with the Registrant.
[F4]The option vests as to 1/48th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continuing employment with the Registrant.
[F5]The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant.

Documents

1 file